NCT07634874尚未招募1 期
A Randomized, Open-Label, 2-period, 2-sequence, Crossover Food-Effect Study of KH607 Tablets in Healthy Chinese Participants
Chengdu Kanghong Pharmaceutical Group Co., Ltd.0 个研究点目标入组 16 人开始时间: 2026年6月1日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 16
研究概览
简要总结
This study is a randomized, open-label, 2-period, 2-sequence, crossover food-effect study designed to evaluate the effect of a high-fat meal on the pharmacokinetics of a single oral dose of KH607 tablets in healthy participants, as well as to assess the safety of a single oral dose of KH607 tablets administered under fasting and fed conditions in healthy participants.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participants must be healthy and aged ≥18 and <45 years at the time of screening visit.
- •Participants must have a body weight equal to or greater than 50 kg (≧45 kg for females ) and a body mass index between 19.0 kg/m2 and 28.0 kg/m2 at the time of screening visit.
- •Participants who have no plans for reproduction during the study period and for 3 months following the last dose, must voluntarily agree to use effective and appropriate contraceptive measures, and must have no plans for sperm or egg donation during this period.
- •Participant who can understand and comply with the study procedures and requirements, and can provide written informed consent prior to any study procedures shall be included
排除标准
- •Participants with known allergy to any ingredient of KH607; or those with a known history of allergy to drugs of the same class; or those with known allergies to two or more other drugs, foods, or environmental factors; or those known to be prone to allergic symptoms such as rash, urticaria, etc. shall be excluded.
- •Participants with diseases of the cardiovascular, nervous, respiratory, urinary, digestive, hematologic, endocrine, or immune systems, or psychiatric disorders (including but not limited to: history of epilepsy, Parkinson's disease or other movement disorders, clinically significant history of syncope or vertigo, and any history of psychiatric disorders), which may affect the safety evaluation of the trial, and who, in the opinion of the investigator, are unsuitable for participation in the trial.
- •Participants with a history of vestibular dysfunction or severe motion sickness; or a history of ocular disorders such as glaucoma, retinopathy, or other ophthalmic diseases that may cause blurred vision or exacerbate visual adverse effects and are considered clinically significant by the investigator shall be excluded.
- •Participants who are unable to Irefrain from driving vehicles, operating hazardous machinery, or working at heights from the time of signing the informed consent form until 1 week after the last dose shall be excluded.
- •Participation who have participated in another clinical trial and received an investigational drug, vaccine, or device within 90 days prior to the first dose shall be excluded.
研究者
相似试验
已完成
1 期
The Food Effect on Pharmacokinetics of Fixed Dose Combination of Gemigliptin/Dapagliflozin/Metformin in Healthy VolunteersNCT07396844LG Chem28
进行中（未招募）
1 期
A Food Effect Study of LY03020 in Healthy SubjectsSchizophreniaNCT07292233Luye Pharma Group Ltd.16
招募中
1 期
ECC4703 Food Effect and Relative Bioavailability Study in Healthy Adult ParticipantsNCT07334080Eccogene72
尚未招募
不适用
Food Trial Evaluating Fecal Abundance of SBD111 With Once-Daily Versus Twice-Daily Administration in Healthy AdultsOsteopeniaMenopause Related ConditionsProbiotic InterventionSynbioticsOsteoporosisNCT07538167Solarea Bio, Inc80
尚未招募
不适用
A clinical study to evaluate the effect of a test product (Meal Replacement Supplement) on weight management in overweight / obese patients.CTRI/2024/04/065016Dr. Reddys Laboratories Ltd.150